Information Sharing in Collaborative Drug Therapy Management Service by Doctors, Medical Technologists and Pharmacists for Prevention of Hepatitis B Virus Reactivation Caused by Cancer Chemotherapy

DOI Web Site 6 Citations 3 References
  • Uchihata Kumiko
    Department of Pharmacy, National Hospital Organization Iwakuni Clinical Center
  • Osaki Seiichi
    Department of Pharmacy, National Hospital Organization Iwakuni Clinical Center
  • Takahashi Kyouhei
    Department of Pharmacy, National Hospital Organization Iwakuni Clinical Center
  • Murakami Teruaki
    Department of Pharmacy, National Hospital Organization Iwakuni Clinical Center
  • Hanamoto Kozue
    Department of Clinical Laboratory, National Hospital Organization Iwakuni Clinical Center
  • Ishida Katsunari
    Department of Clinical Laboratory, National Hospital Organization Iwakuni Clinical Center
  • Miyashita Manabi
    Department of Hepatology, National Hospital Organization Iwakuni Clinical Center
  • Kuyama Shoichi
    Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center
  • Yoshida Akimasa
    Department of Pharmacy, National Hospital Organization Okayama Medical Center
  • Nigota Motofumi
    Department of Pharmacy, National Hospital Organization Shikoku Cancer Center

Bibliographic Information

Other Title
  • がん化学療法によるB型肝炎ウイルス再活性化予防に関する医師・臨床検査技師・薬剤師による共同薬物治療管理と情報共有

Search this article

Abstract

<p>Recently, the high mortality rate resulting from the reactivation of hepatitis B virus (HBV) through the use of immunosuppressive therapy or chemotherapy for fulminant hepatitis patients has been recognized as one of the most critical medical issues.</p><p>On May 19, 2014, we started a collaborative drug therapy management (HBV-CDTM) project to establish a preventive procedure that can be used to avoid HBV reactivation. Before starting the project, the project protocol developed by the commission of chemotherapy was approved by the Director of Iwakuni Clinical Center. We decided to manage the HBV screening demonstrated in the hepatitis B treatment guidelines in collaboration with pharmacists, doctors and medical technologists. To fill in clinical records when conducting HBV-CDTM, we used the “eXChart” of the electronic clinical record system “HOPE/EGMAIN-GX” to simplify tasks, information sharing among medical staff members with different duties and collection of electronic clinical data.</p><p>From May 19, 2014 to January 31, 2015, we applied HBV-CDTM to 211 patients in total, and found three patients (1.4%) were hepatitis B surface antigen (HBsAg)-positive, and 75 patients (35.5%) were hepatitis B core antibody positive and/or hepatitis B surface antibody-positive despite being HBsAg-negative. We extracted 78 high-risk patients of HBV reactivation through HBV-CDTM. In addition, the operation rate of HBV screening examination after the introduction of HBV-CDTM rose to 98.6% from that of 3.2% before introduction.</p><p>Through the HBV-CDTM project, we concluded that the introduction of HBV-CDTM enabled reduction of doctors' loads and enhanced the preventive procedure against HBV reactivation.</p>

Journal

Citations (6)*help

See more

References(3)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top